Forty years of the international association for study of lung cancer pathology committee.
Lung cancer classification during the last four decades has undergone major changes and evolution, mostly lead by pathologists who were actively involved in the International Association for the Study of Lung Cancer (IASLC) Pathology Committee. The Committee members have led the development and writing of the second (1981), third (1999 and 2004), and fourth (2015) editions of the World Health Organization classifications on lung tumors. Committee members were responsible for defining and refining the classifications of small-cell carcinoma and adenocarcinoma subtypes that are relevant to their clinical behavior. Particularly notable was development of the 2011 IASLC/American Thoracic Society/European Respiratory Society international, multidisciplinary lung adenocarcinoma classification. The multidisciplinary approach that represents the IASLC culture in research, education, and practice in clinical management of lung cancer patients have paved the way for integrating pathology practice into the new era of personalized cancer care.
*Department of Pathology, University Health Network-Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada; †Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York; ‡Département d'Anatomie et de Pathologique Cytologiques, CHU Albert Michallon INSERM U823/Université Joseph Fourier, Grenoble, France; §Department of Histopathology, Royal Brompton Hospital, London, United Kingdom; ‖Department of Pathology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan; and ¶University of Colorado Cancer Center, Department of Pathology and Division of Medical Oncology, University of Colorado Denver, Aurora, Colorado.
Ming-Sound
MS
Tsao
William D
WD
Travis
Elisabeth
E
Brambilla
Andrew G
AG
Nicholson
Masayuki
M
Noguchi
Fred R
FR
Hirsch
D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology*; D010606:Pharmacy and Therapeutics Committee; D055752:Small Cell Lung Carcinoma / Q000473:pathology